A phase I, open-label, dose-escalation study investigating a low-density lipoprotein receptor-related protein (LRP) 5/6 inhibitor, BI 905677, in patients with advanced solid tumors.

被引：0
|
作者：
Elez, Elena [1 ]
Lenz, Heinz-Josef [2 ]
de Jonge, Maja [3 ]
Yaeger, Rona [4 ]
Doi, Toshihiko [5 ]
Pronk, Linda [6 ]
Teufel, Michael [7 ]
Marzin, Kristell [8 ]
Tabernero, Josep [1 ]
机构：
[1] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[3] Erasmus Med Ctr Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
[5] Natl Canc Ctr Hosp East, Chiba, Japan
[6] Boehringer Ingelheim Espana SA, Clin Dev Oncol, Madrid, Spain
[7] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[8] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT514
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase I dose-escalation study of INCB028060, an inhibitor of c-MET receptor tyrosine kinase, in patients with advanced solid tumors.
    Donehower, R. C.
    Scardina, A.
    Hill, M.
    Bowman, J.
    Newton, R. C.
    Liu, X.
    Scherle, P.
    Wang, Q.
    Diamond, S.
    Boer, J.
    Lee, F.
    Gau, T.
    Burris, H. A.
    Bendell, J. C.
    Jones, S. F.
    Infante, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors.
    Park, Jong Chul
    Butler, Marcus O.
    Curti, Brendan D.
    Emens, Leisha A.
    Pastor, Danielle M.
    Elassal, Joseph
    Kaufman, Howard L.
    Kirkwood, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
    Rodon, Jordi
    Tawbi, Hussein A.
    Thomas, Anne L.
    Stoller, Ronald G.
    Turtschi, Christian P.
    Baselga, Jose
    Sarantopoulos, John
    Mahalingam, Devalingam
    Shou, Yaping
    Moles, Melissa A.
    Yang, Lin
    Granvil, Camille
    Hurh, Eunju
    Rose, Kristine L.
    Amakye, Dereck D.
    Dummer, Reinhard
    Mita, Alain C.
    CLINICAL CANCER RESEARCH, 2014, 20 (07) : 1900 - 1909
  • [24] A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
    Voss, Martin H.
    Hierro, Cinta
    Heist, Rebecca S.
    Cleary, James M.
    Meric-Bernstam, Funda
    Tabernero, Josep
    Janku, Filip
    Gandhi, Leena
    Iafrate, A. John
    Borger, Darrell R.
    Ishii, Nobuya
    Hu, Youyou
    Kirpicheva, Yulia
    Nicolas-Metral, Valerie
    Pokorska-Bocci, Anna
    Chessex, Anne Vaslin
    Zanna, Claudio
    Flaherty, Keith T.
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2019, 25 (09) : 2699 - 2707
  • [25] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Andrea Wang-Gillam
    William Schelman
    Stacey Ukrainskyj
    Caly Chien
    Martha Gonzalez
    Zhao Yang
    Marek Kania
    Heather Yeckes-Rodin
    Investigational New Drugs, 2023, 41 (6) : 851 - 860
  • [26] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Wang-Gillam, Andrea
    Schelman, William
    Ukrainskyj, Stacey
    Chien, Caly
    Gonzalez, Martha
    Yang, Zhao
    Kania, Marek
    Yeckes-Rodin, Heather
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 851 - 860
  • [27] Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors
    Angevin, Eric
    Elez, Elena
    Cohen, Steven J.
    Van Laethem, Jean-Luc
    Ottensmeier, Christian
    Joly, Florence
    Ray-Coquard, Isabelle
    Lopez-Martin, Jose A.
    Dirix, Luc
    Machiels, Jean-Pascal
    Clive, Sally
    Steven, Neil Matthew
    Reddy, Manjula
    Hall, Brett
    Puchalski, Thomas
    Bandekar, Rajesh
    Van de Velde, Helgi
    Tromp, Brenda J.
    Vermeulen, Jessica
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] A phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) with advanced solid tumors.
    Messersmith, W. A.
    LoRusso, P.
    Cleary, J. M.
    Dasari, A.
    Zhang, X.
    Shaik, M. N.
    Courtney, R. D.
    Randolph, S.
    Shapiro, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
    Desai, Jayesh
    Gan, Hui
    Barrow, Catherine
    Jameson, Michael
    Atkinson, Victoria
    Haydon, Andrew
    Millward, Michael
    Begbie, Stephen
    Brown, Michael
    Markman, Ben
    Patterson, William
    Hill, Andrew
    Horvath, Lisa
    Nagrial, Adnan
    Richardson, Gary
    Jackson, Christopher
    Friedlander, Michael
    Parente, Phillip
    Tran, Ben
    Wang, Lai
    Chen, Yunxin
    Tang, Zhiyu
    Huang, Wendy
    Wu, John
    Zeng, Dewan
    Luo, Lusong
    Solomon, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (19) : 2140 - +
  • [30] A phase I/II, open-label, dose-escalation, and cohort-expansion study evaluating the safety, pharmacokinetics, and therapeutic activity of OBI-999 in patients with advanced solid tumors.
    Tsimberidou, Apostolia Maria
    Ajani, Jaffer A.
    Hsu, Pei
    Chen, I-Ju
    Pearce, Tillman E.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345